Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-06
2007-11-06
Richter, Johann (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S322000, C546S199000, C548S304700
Reexamination Certificate
active
11188295
ABSTRACT:
Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1and/or M4receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.
REFERENCES:
patent: 4254127 (1981-03-01), Vandenberk et al.
patent: 4861889 (1989-08-01), Helsley et al.
patent: 5707798 (1998-01-01), Brann
patent: 5718912 (1998-02-01), Thomspon et al.
patent: 5726188 (1998-03-01), Takano et al.
patent: 5756508 (1998-05-01), Thompson et al.
patent: 5789425 (1998-08-01), Takano et al.
patent: 6586435 (2003-07-01), Cereda et al.
patent: 6649705 (2003-11-01), Ramesh
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6951849 (2005-10-01), Kelly et al.
patent: 7087593 (2006-08-01), Kelly et al.
patent: 0 816 362 (1998-01-01), None
patent: 1017613 (1966-01-01), None
patent: WO 96/13262 (1996-05-01), None
patent: WO 97/16186 (1997-05-01), None
patent: WO 97/16187 (1997-05-01), None
patent: WO 97/16192 (1997-05-01), None
patent: WO 99/32481 (1999-07-01), None
patent: WO 01/83472 (2001-11-01), None
patent: WO 02/24662 (2002-03-01), None
patent: WO 03/028650 (2003-04-01), None
patent: WO 03/028650 A22 (2003-04-01), None
Vyas et al., Domperidone Maleate, Acta Crystallographica, Section C: Crystal Structure Communications 1999, C55 (9), ii, IUC9900104.
Bodick et al., Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in alzheimer disease, Arch. Neurol. 54:465 (1997).
Bonner et al, Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes, Neuron 1:403 (1988).
Bonner et al., Identification of a family of muscarinic acetylcholine receptor genes, Science 237:527 (1987).
Braüner-Osborne, H.B. and Brann, M.R., Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells, Eur. J. Pharmacol. 295:93-102 (1996).
Bymaster et al., Potential role of muscarinic receptors in schizophrenia, Life Sci. 64:527 (1999).
Bymaster et al., Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R, 6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane, Eur. J. Pharmacol. 356:109 (1998).
Cakir, et al., Synthesis and antinociceptive activity of some 3-substituted benzothiazolone derivatives, II Farmaco, 54:846 (1999).
Chahine, M. et al., Functional expression and properties of the human skeletal muscle sodium channel, Pfluegers Arch. 427:136-142 (1994).
Felder, et al., Therapeutic opportunities for muscarinic receptors in the central nervous system, J. Med. Chem. 43:4333 (2000).
Friedman, et al., Pharmacologic strategies for augmenting cognitive performance in schizophrenia, Biol. Psychiatry, 45:1 (1999).
Rowley, et al., Current and novel approaches to the drug treatment of schizophrenia, J. Med. Chem. 44:477 (2001).
Sauerberg, et al., Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity, J. Med Chem. 41:4378 (1998).
Shannon et al., Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1receptors, J. Pharmacol. Exp. Ther. 269:271 (1994).
Shannon et al., Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats, J. Pharmacol. Exp. Ther. 290:901 (1999).
Shannon et al., Xanomeline, an M1/M4preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice, Schizophrenia Res. 42:249 (2000).
Stormann et al., Molecular cloning and expression of a dopamine D2 receptor from Human retina, Mol. Pharmacol. 37:1-6 (1990 ).
H. Itani, et al., “Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptors,”Bioorganic&Medicinal Chemistry Letters, vol. 12 (2002) 799-802.
Supplementary European Search Report for Application No. EP 02 76 3824, Sep. 22, 2005.
Bodick, et al., “Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in alzheimer disease”,Arch. Neurol., (1997) 54:465.
Bonner, et al., “Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes”,Neuron, (1988) 1:403.
Bonner, et al., “Identification of a family of muscarinic acetylcholine receptor genes”,Science, (1987) 237:527.
Braüner-Osborne, et al., “Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells”,Eur. J. Pharamacol., (1996) 295:93-102.
Bymaster, et al., “Potential role of muscarinic receptors in schizophrenia”,Life Science, (1999) 64:527.
Bymaster, et al., “Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-y1)-1-azabicyclo[3.2.1]octane”,Eur. J. Pharmacol., (1998) 356:109.
Cakir, et al., “Synthesis and antinociceptive activity of some 3-subsitiuted benzothiazolone derivatives”II Farmaco, (1999) 54:846.
Chahine, et al., “Functional expression and properties of the human skeletal muscle sodium channel”,Pfluegers Arch., (1994) 427:136-142.
Felder, et al., “Therapeutic opportunities for muscarinic receptors in the central nervous system”,J. Med. Chem., (2000) 43:4333.
Friedman, et al., “Pharmacologic strategies for augmenting cognitive performance in schizophrenia”,Biol. Psychiatry, (1999) 45:1.
Itani, et al., “Novel Potent Antagonists of Human Neuropeptide Y Y5 Receptors”,Bioorganic&Medicinal Chemistry Letters, (2002) 12:799-802.
Rowley, et al., “Current and novel approaches to the drag treatment of schizophrenia”,J. Med. Chem., (2001) 44:477.
Sauerberg, et al., “Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity”,J. Med. Chem., (1998) 41:4378.
Shannon, et al., “Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M receptors”,J. Pharmacol. Exp. Ther., (1994) 269:271.
Shannon, et al., “Muscarinic receptor agonists, like dopamine receptors antagonist antipsychotics, inhibit conditioned avoidance response in rats”,J. Pharmacol. Exp. Ther., (1999) 290:901.
Shannon, et al., “Xanomeline, an M1/M4preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice”,Schizophrenia Res., (2000) 42:249.
Stormann, et al., “Molecular cloning and expression of a dopamine D2 receptor from Human retina”,Mol. Pharmacol., (1990) 37:1-6.
Supplementary European Search Report for Application No. EP 02 76 3824, Sep. 22, 2005.
Verma, et al., “Synthesis and Antibacterial Activity of Certain 3-Substituted Benzoxazolinones”, J. Pharm. Sciences, (1968) 57(1):39-44.
Kelly Nicholas Michael
Koch Kristian Norup
Tolf Bo-Ragnar
ACADIA Pharmaceuticals Inc.
Knobbe Martens Olson & Bear LLP
Nwaonicha Chukwuma
Richter Johann
LandOfFree
Benzimidazolidinone derivatives as muscarinic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzimidazolidinone derivatives as muscarinic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzimidazolidinone derivatives as muscarinic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861044